title: [PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer].
abstract: Among many cancer cells signaling pathways, PI3K-AKT-mTOR plays a major role in growth, proliferation and cellular survival. This is a complex pathway activated either by an extracellular way (receptors with tyrosine kinase activity) or by an intracellular way with transformed or overexpressed proteins involved in the signal transduction. To date, there are many applications of mTOR inhibitors in oncology with an expanding development rapidly. However, resistances appear to mTOR inhibitors which lead to 2nd generation mTOR inhibitors development. A better knowledge of predictive and prognostic biomarkers will allow to specify the group of patients who may benefit from these treatments and help to the choice.
authors.affiliation: CHU Estaing-Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 01, France. Electronic address: thibaultbrotelle@yahoo.fr.
authors.forename: Thibault
authors.initials: T
authors.lastname: Brotelle
authors.affiliation: CHU Estaing-Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand cedex 01, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy; D049109:Cell Proliferation; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000209:etiology; D018358:Neuroendocrine Tumors / Q000188:drug therapy; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D014402:Tuberous Sclerosis / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human
keywords: Biomarker; Everolimus; Inhibiteur mTOR; Marqueur biologique; PI3K-AKT-mTOR; Resistance; Résistance; Temsirolimus; mTOR inhibitor; Évérolimus